Motexafin gadolinium

Generic Name: Motexafin gadolinium

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₇₂GdN_₅O_₁₄

CAS Number: 246252-06-2

Unique Ingredient Identifier: 0BG5NE3APZ

Background: Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.

Indication: Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Leukemia
Leukemia, Lymphocytic, Chronic

First Posted Date: 2004-01-26

Last Posted Date: 2014-06-26

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 27

Registration Number: NCT00076401

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-12-02

Last Posted Date: 2009-02-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00003409

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

First Posted Date: 2003-08-20

Last Posted Date: 2019-09-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 200

Registration Number: NCT00003736

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

and more 9 locations

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: motexafin gadolinium
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00005065

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Phase 3

Completed

Conditions: Brain Neoplasms
Carcinoma, Non-Small-Cell Lung
Metastases, Neoplasm

First Posted Date: 2003-02-13

Last Posted Date: 2007-05-08

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 550

Registration Number: NCT00054795

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Colorectal Cancer
Head and Neck Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic/Myeloproliferative Diseases
Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2019-12-17

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00036790

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Procedure: conventional surgery
Radiation: 3-dimensional conformal radiation therapy
Radiation: stereotactic radiosurgery
Drug: motexafin gadolinium
Procedure: magnetic resonance imaging
Procedure: spectroscopy

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00004262

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00032097

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Phase 1

Completed

Conditions: Untreated Childhood Brain Stem Glioma

Interventions: Drug: motexafin gadolinium
Radiation: radiation therapy
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00003909

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy